Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance

Abstract

<b>Aim:</b> Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. <b>Clinical efficacy:</b> Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. <b>Safety:</b> Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. <b>Conclusion:</b> Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.